Here we used an immune-competent murine model of Myc-amplified Group 3 medulloblastoma to investigate changes in intracerebral immune cell populations induced by tumor growth, and for the first time describe the impact of several first line medulloblastoma therapies on the immune microenvironment. The gene discussed is MYC; the disease is neoplasm.